Last reviewed · How we verify
NCT04707989
Tolerance and Safety of a Ketone-Promoting Food Ingredient
NA trial testing Ketone- Promoting Food Ingredient #1 in Tolerance in 90 participants. Completed in 5 March 2021.
5 March 2021
Quick facts
| Lead sponsor | BHB Therapeutics, Ireland LTD |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 90 |
| Start date | 11 December 2020 |
| Primary completion | 5 March 2021 |
| Estimated completion | 5 March 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ketone- Promoting Food Ingredient #1
- Ketone- Promoting Food Ingredient #2
- Ketone Free Placebo
Conditions studied
- Tolerance — all drugs for Tolerance →
Sponsor
BHB Therapeutics, Ireland LTD
Who can join
Adults 18 to 65, any sex, with Tolerance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to capture information on tolerance and safety of a ketone-promoting food ingredient in healthy adults.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults.
Chen O, Blonquist TM, Mah E, Sanoshy K, et al · · 2021 · cited 31× · PMID 34208742 · DOI 10.3390/nu13062066
Verify or expand the search:
- PubMed search for NCT04707989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tolerance
Currently open trials in the same condition.
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting
- NCT05022420 — SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases · recruiting
- NCT06286488 — Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza · Phase 4 · active not recruiting
Other BHB Therapeutics, Ireland LTD trials
Trials by the same sponsor.
- NCT05686083 — Pharmacokinetics of Two Fatty Acid Ketone Esters · NA · completed
- NCT05310058 — Pharmacokinetics of C6 Ketone Di-ester · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04707989 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BHB Therapeutics, Ireland LTD
- Last refreshed: 10 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04707989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing